1. WHO classificaiton of tumours haematopoietic and lymphoid tissues;Swerdlow,2017
2. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas;Tsuyama;Oncotarget,2017
3. Aberrant expression of T cell and B cell markers in myelocyte/monocyte/histiocyte-derived lymphoma and leukemia cells. Is the infrequent expression of T/B cell markers sufficient to establish a lymphoid origin for Hodgkin's Reed-Sternberg cells?;Hsu;Am J Pathol,1989
4. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy;Tan;Cancer Commun (Lond),2020
5. The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation;Taube;J Immunother Cancer,2020